Abbott Labs Files 8-K on Financials

Ticker: ABT · Form: 8-K · Filed: 2025-04-16T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-K

Related Tickers: ABT

TL;DR

ABT filed an 8-K on 4/16/25 covering financial results and exhibits.

AI Summary

Abbott Laboratories filed an 8-K on April 16, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. The filing details the company's corporate information, including its incorporation in Illinois and its principal executive offices located at 100 Abbott Park Road, Abbott Park, Illinois.

Why It Matters

This filing provides investors with crucial updates on Abbott Laboratories' financial performance and condition, enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual events or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Abbott Laboratories' Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on April 16, 2025.

Where are Abbott Laboratories' principal executive offices located?

Abbott Laboratories' principal executive offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

In which state was Abbott Laboratories incorporated?

Abbott Laboratories was incorporated in Illinois.

What is the IRS Employer Identification Number for Abbott Laboratories?

The IRS Employer Identification Number for Abbott Laboratories is 36-0698440.

From the Filing

0001628280-25-017924.txt : 20250416 0001628280-25-017924.hdr.sgml : 20250416 20250416073602 ACCESSION NUMBER: 0001628280-25-017924 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250416 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250416 DATE AS OF CHANGE: 20250416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 25841234 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20250416.htm 8-K abt-20250416 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2025-04-16 2025-04-16 0000001800 exch:XCHI 2025-04-16 2025-04-16 0000001800 exch:XNYS 2025-04-16 2025-04-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On April 16, 2025, Abbott Laboratories announced its results of operations for the first quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to busin

View on Read The Filing